Esperion Therapeutics (ESPR) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Key business developments

• Achieved a transformative year with label expansion, broadening the addressable U.S. patient population from 10 million to 70 million, now including primary prevention patients.

• Addressed capital structure issues and secured significant payer wins following the label expansion.

• Monetized European royalty stream for $305 million, cleaning up the balance sheet and retaining future upside.

• Expanded U.S. coverage to 144 million patients under new label and utilization management (UM) criteria, representing 96% of target coverage.

• Maintained stable pricing with minimal net price concessions despite expanded access.

Clinical and market impact

• CLEAR Outcomes trial showed a 23% reduction in fatal and non-fatal MI and a 30% reduction in MACE-4 events for primary prevention, supporting label expansion.

• Growth is primarily driven by the primary prevention segment, with most patients previously or currently on statins.

• Prescription growth accelerated post-label update, with 11% month-over-month growth after June 1 payer changes.

• Prescribing base now includes 21,000 prescribers, with a 60% primary care and 40% cardiologist split; primary care growth outpaces cardiology.

• Digital and direct marketing efforts reach 40,000 physicians, amplifying commercial impact.

Strategic outlook and future plans

• Current sales and marketing investment is $200–210 million annually, with a focus on reallocating resources to high-return tactics.

• Product is positioned as a billion-dollar opportunity, leveraging digital programs and targeted field force.

• Ex-U.S. growth strong, with nearly all European countries launched and positive phase III results in Japan; additional regulatory milestones expected.

• Confident in IP protection until at least 2031, with potential to extend through method of use and formulation patents.

• Pipeline includes next-generation ATP citrate lyase inhibitors, with plans to discuss further at an R&D day in the first half of next year; future focus may expand beyond cardiovascular indications.